What is the link between the European and the British Pharmacopoeia?

19.08.2019

Question of the Week

The texts and monographs of the European Pharmacopoeia are also an integral part of the British Pharmacopoeia. In addition, the British Pharmacopoeia provides for monographs for individual drug products and for a range of drug substances that are not the subject of the monographs in the Ph. Eur. When a monograph is adopted from the European Pharmacopoeia, it is marked in the BP by the European star circle next to the title.

[GMP Compliance Adviser, Chapter 14.K.5]

Would you like to discover more?

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.

The free demo access is non-binding and ends automatically after 7 days.

Test it now for free

You may also be interested in the following articles:

09.10.2026

News

Annex 22: Results of the EMA Workshop

On 30 June, the EMA’s Annex 22 Working Group discussed the future scope of the annex with AI experts and representatives of the pharmaceutical industry (as previously reported).

08.10.2026

News

EMA Workshop Regarding Annex 22 "Artifical Intelligence"

The current draft of Annex 22, "Artificial Intelligence", proposes excluding generative AI and large language models (LLMs), as well as probabilistic, dynamic and adaptive AI models, from critical GMP applications. Numerous comments submitted during the public consultation challenged this approach. Instead, the aim should be to support innovation and encourage investment by the pharmaceutical industry.

05.10.2026

Question of the Week

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

05.10.2026

LOGFILE Feature

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

02.10.2026

News

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

02.10.2026

News

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.